Abbreviated Name

Lung Ref Set A App: Hirschowitz (2009)

Lead Investigator

Hirschowitz, Edward — University of Kentucky

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Srivastava, Sudhir — National Cancer Institute
• Ujhazy, Peter — National Cancer Institute
• Hirschowitz, Edward — University of Kentucky

Abstact

Aims

Aim 1. To pre-validate assay performance in a high-risk clinical population from an alternate demographic. We intend to validate the predictive accuracy of our markers for clinically diagnosed lung cancer, identify the limits of the assay in individuals with benign lung disease, and determine marker specificity for lung vs. other cancers. Pre-validation will define performance in samples from an alternate demographic and generate classifiers with which to construct optimalperformance criteria that can be applied to class prediction for subsequent blinded analysis of a larger EDRN clinical reference set.

Analytic Method

Assay. The diagnostic chip includes capture proteins for the most predictive markers and empty T7 phage controls in replicates of eight, randomly distributed across the chip. The methodology for all studies will be identical to that described in published manuscripts and preliminary results section.

Biomarkers

• T7 (25 markers)

Data Collections

• No data available at this time for this protocol

Protocol ID

279

Field of Research

Proteomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

1